From Nasdaq: 2024-06-04 11:45:00

Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) have surged over the past year due to high demand for weight-loss drugs, with Eli Lilly up over 89% and Novo Nordisk up over 73%. The global obesity epidemic is expected to impact over half the population by 2035, driving the market for weight-loss drugs to potentially reach $130 billion by 2030.

GLP-1 medications, used to treat diabetes and promote weight loss, have shown potential to slow Parkinson’s symptoms and improve sleep apnea. Companies like Eli Lilly and Novo Nordisk are expected to dominate this market, with 232 new weight-loss medications in development aiming to reduce costs and side effects.

Investing in the weight-loss drug market is now easier with ETFs like Tema Obesity & Cardiometabolic ETF (HRTS), Roundhill GLP-1 & Weight Loss ETF (OZEM), and Amplify Weight Loss Drug & Treatment ETF (THNR). These ETFs offer exposure to companies at the forefront of developing weight-loss medications, providing investment opportunities in this booming sector.



Read more at Nasdaq: ETFs to Profit from the Weight Loss Drug Boom